BRIEF—Positive UK reimbursement outcome for Adtralza

In the UK, the National Institute for Health and Care Excellence (NICE) has given a positive reimbursement decision on Leo Pharma’s interleukin (IL)-13 blocker Adtralza (tralokinumab).

The decision will unlock funding in England and Wales, providing access for certain adults with moderate-to-severe atopic dermatitis.

To be eligible, patients must have already tried at least one systemic immunosuppressant, or be ineligible for this kind of treatment.

The NICE’s Final Appraisal Document (FAD) is based upon both a cost-effectiveness analysis and a demonstration of positive patient outcomes, with data from four Phase III studies taken into consideration.

Anthony Bewley, a consultant dermatologist at the Barts Health NHS Trust, said the decision “offers significant new treatment options for atopic dermatitis patients and is an essential step in improving patient experience and quality of life in England and Wales.”